ArticleFrontiers in cardiovascular medicine2026
Effect of dapagliflozin on heart failure with reduced ejection fraction in children.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy and safety of dapagliflozin therapy in children with heart failure with reduced ejection fraction. Methods: This was a retrospective cohort study based on electronic medical records. For the retrospective cohort study, 32 children with heart failure with reduced ejection fraction diagnosed at Shanghai Children's Medical Center and Fujian Children's Hospital from June 2021 to June 2023 and who were treated with dapagliflozin were enrolled. For pediatric patients weighing <10 kg, dapagliflozin was administered at a dosage of 0.2 mg/kg/d. Patients with a body weight ranging from 10 kg to less than 20 kg (20 > weight ≥10 kg) received dapagliflozin at a dose of 2.5 mg/d. Those weighing between 20 kg and less than 30 kg (30 > weight ≥20 kg) were prescribed dapagliflozin at 5 mg/d. For patients weighing 30 kg or more, the initial dose of dapagliflozin was 5 mg/d, which was increased to 10 mg/d after one month. 42 children treated during the same period without dapagliflozin were included as the control group. All children were treated with standard guideline-directed triple combination of ACEI/ARNI, Results: Among the 32 children, 20 were male and 12 were female, aged (6.32 ± 4.00) years; weight (22.19 ± 12.66) kg. The underlying diseases included dilated cardiomyopathy in 25 cases, dilated cardiomyopathy combined with complete left bundle branch block in two cases, postoperative congenital heart disease in four cases, and atrial tachycardia in one case. At 24 (±2) weeks of treatment, left ventricular ejection fraction level significantly increased compared with baseline ( Conclusion: Dapagliflozin was associated with improvements in left ventricular ejection fraction, BNP, and NYHA cardiac function classification in children with heart failure with reduced ejection fraction. No hospitalization or death due to the deterioration of heart failure and no serious adverse reactions were observed. The treatment was generally well tolerated, and the weight-stratified dosing strategy showed acceptable short-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.